At a glance
ClinicalIndex Comparison RecordN/ACompleted· 807 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy.
In Brief
An observational study for HIV/AIDS. Completed, enrolled 807 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate cumulative exposure to tenofovir diphosphate (TFV-DP) using dried blood spots (DBS) in treated HIV-infected patients who are receiving a TFV-based regimen. Using DBS will allow the investigators to assess this simple method to measure drug exposure in the clinical setting. The investigators hypothesize that TFV-DP levels will be lowest in individuals with a detectable viral load and highest in those with viral suppression.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV/AIDS
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartDec 2013
First PostedDec 2013
Primary CompletionJul 2017
TodayJul 2026
First PostedDec 16, 2013
Enrollment StartDec 1, 2013
Primary CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 12.5 years ago